Entacapone (BioDeep_00000006635)
Secondary id: BioDeep_00000399136
human metabolite Chemicals and Drugs
代谢物信息卡片
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
化学式: C14H15N3O5 (305.1012)
中文名称: 恩他卡朋
谱图信息:
最多检出来源 Rattus norvegicus(natural_products) 2.24%
分子结构信息
SMILES: CCN(CC)C(=O)/C(=C/c1cc(c(c(c1)O)O)[N+](=O)[O-])/C#N
InChI: InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3
描述信息
Entacapone is an inhibitor drug of catechol O-methyltransferase, which catalyzes the reaction between catechol and S-adenosyl-L-methionine to produce guaiacol and S-adenosyl-L-homocysteine. [HMDB]
Entacapone is an inhibitor drug of catechol O-methyltransferase, which catalyzes the reaction between catechol and S-adenosyl-L-methionine to produce guaiacol and S-adenosyl-L-homocysteine.
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
同义名列表
14 个代谢物同义名
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; (e)-Α-cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; (e)-a-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; Novartis brand OF entacapone; Orion brand OF entacapone; Entacaponum; Entacapona; Entacapone; Comtess; Comtan; Entacapone
数据库引用编号
19 个数据库交叉引用编号
- ChEBI: CHEBI:4798
- KEGG: C07943
- KEGGdrug: D00781
- PubChem: 5281081
- HMDB: HMDB0012226
- DrugBank: DB00494
- ChEMBL: CHEMBL953
- Wikipedia: Entacapone
- MetaCyc: CPD-7662
- foodb: FDB028870
- chemspider: 4444537
- CAS: 130929-57-6
- CAS: 116314-67-1
- PMhub: MS000019706
- PubChem: 10145
- PDB-CCD: PD9
- NIKKAJI: J506.416C
- RefMet: Entacapone
- KNApSAcK: 4798
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
1 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yogeeta Agrawal, Kiran Patil, Hitendra Mahajan, Mrugendra Potdar, Pratiksha Joshi, Kartik Nakhate, Charu Sharma, Sameer N Goyal, Shreesh Ojha. In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach.
Drug delivery.
2022 Dec; 29(1):1112-1121. doi:
10.1080/10717544.2022.2058651. [PMID: 35380091] - Jiahong Yang, Xiaolin Sun, Ning Huang, Peng Li, Jiaqi He, Lan Jiang, Xuemei Zhang, Shu Han, Hong Xin. Entacapone alleviates acute kidney injury by inhibiting ferroptosis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2022 07; 36(7):e22399. doi:
10.1096/fj.202200241rr. [PMID: 35691001] - Eslam Hassan, Shady Allam, Ahmed M Mansour, Aya Shaheen, Salama A Salama. The potential protective effects of estradiol and 2-methoxyestradiol in ischemia reperfusion-induced kidney injury in ovariectomized female rats.
Life sciences.
2022 May; 296(?):120441. doi:
10.1016/j.lfs.2022.120441. [PMID: 35240160] - Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Cells.
2022 04; 11(9):. doi:
10.3390/cells11091511. [PMID: 35563817] - Olaf Krause, Lis-Femke Griebel, Johannes Heck. [78-year-old patient with urine discoloration].
Deutsche medizinische Wochenschrift (1946).
2022 Jan; 147(1-02):15-16. doi:
10.1055/a-1702-7638. [PMID: 34963169] - Hui Min, Shuangyan Wu, Zongsu Han, Zhonghang Chen, Tiankai Sun, Wei Shi, Peng Cheng. Fast Detection of Entacapone by a Lanthanide-Organic Framework with Rhombic Channels.
Chemistry (Weinheim an der Bergstrasse, Germany).
2021 Dec; 27(69):17459-17464. doi:
10.1002/chem.202103297. [PMID: 34608690] - Maral Aminpour, Williams Ernesto Miranda Delgado, Soren Wacker, Sergey Noskov, Michael Houghton, D Lorne J Tyrrell, Jack A Tuszynski. Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19.
BMC pharmacology & toxicology.
2021 10; 22(1):61. doi:
10.1186/s40360-021-00519-5. [PMID: 34674775] - Nir Giladi, Tanya Gurevich, Ruth Djaldetti, Liat Adar, Ryan Case, Shelly Leibman-Barak, Nissim Sasson, Yoseph Caraco. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Parkinsonism & related disorders.
2021 10; 91(?):139-145. doi:
10.1016/j.parkreldis.2021.09.024. [PMID: 34619438] - Eman Soliman, Samar M Shewaikh, Ahmed Fahmy, Shimaa Elshazly. Entacapone scavenges peroxynitrite and protects against kidney and liver injuries induced by renal ischemia/reperfusion in rats.
International urology and nephrology.
2021 Aug; 53(8):1713-1721. doi:
10.1007/s11255-021-02827-5. [PMID: 33675481] - Chumpol Anamnart, Ram Kitjarak. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2021 Jun; 88(?):226-231. doi:
10.1016/j.jocn.2021.03.047. [PMID: 33992189] - Aaro Jalkanen, Veera Lassheikki, Tommi Torsti, Elham Gharib, Marko Lehtonen, Risto O Juvonen. Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Mar; 51(3):268-278. doi:
10.1080/00498254.2020.1853850. [PMID: 33289420] - Ebrahim Naghian, Faezeh Shahdost-Fard, Mostafa Najafi, Mohammad Reza Manafi, Leila Torkian, Mehdi Rahimi-Nasrabadi. Voltammetric measurement of entacapone in the presence of other medicines against Parkinson's disease by a screen-printed electrode modified with sulfur-tin oxide nanoparticles.
Mikrochimica acta.
2021 02; 188(3):92. doi:
10.1007/s00604-021-04733-0. [PMID: 33608774] - M Senek, D Nyholm, E I Nielsen. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Scientific reports.
2020 10; 10(1):18057. doi:
10.1038/s41598-020-75052-2. [PMID: 33093598] - Angela Valderrama Parizotto, Ana Paula Ferro, Rogério Marchiosi, Flávia Carolina Moreira-Vilar, Jennifer Munik Bevilaqua, Wanderley Dantas Dos Santos, Flávio Augusto Vicente Seixas, Osvaldo Ferrarese-Filho. Entacapone improves saccharification without affecting lignin and maize growth: An in silico, in vitro, and in vivo approach.
Plant physiology and biochemistry : PPB.
2020 Jun; 151(?):421-428. doi:
10.1016/j.plaphy.2020.03.053. [PMID: 32289635] - Saima Aftab, Goksu Ozcelikay, Sevinc Kurbanoglu, Afzal Shah, Faiza Jan Iftikhar, Sibel A Ozkan. A novel electrochemical nanosensor based on NH2-functionalized multi walled carbon nanotubes for the determination of catechol-orto-methyltransferase inhibitor entacapone.
Journal of pharmaceutical and biomedical analysis.
2019 Feb; 165(?):73-81. doi:
10.1016/j.jpba.2018.11.050. [PMID: 30503895] - Kyungbo Kim, Fang Zheng, Chang-Guo Zhan. Oligomerization and Catalytic Parameters of Human UDP-Glucuronosyltransferase 1A10: Expression and Characterization of the Recombinant Protein.
Drug metabolism and disposition: the biological fate of chemicals.
2018 10; 46(10):1446-1452. doi:
10.1124/dmd.118.082495. [PMID: 30111624] - Ali R Jalalvand, Sirous Ghobadi, Hector C Goicoechea, Hui-Wen Gu, Esmael Sanchooli. Investigation of interactions of Comtan with human serum albumin by mathematically modeled voltammetric data: A study from bio-interaction to biosensing.
Bioelectrochemistry (Amsterdam, Netherlands).
2018 Oct; 123(?):162-172. doi:
10.1016/j.bioelechem.2018.05.008. [PMID: 29778043] - Karnell L Grimes, Connor M Stuart, Justin J McCarthy, Baljinder Kaur, Emilio J Cantu, Sarah C Forester. Enhancing the Cancer Cell Growth Inhibitory Effects of Table Grape Anthocyanins.
Journal of food science.
2018 Sep; 83(9):2369-2374. doi:
10.1111/1750-3841.14294. [PMID: 30070707] - David Grünig, Andrea Felser, Urs Duthaler, Jamal Bouitbir, Stephan Krähenbühl. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.
Toxicological sciences : an official journal of the Society of Toxicology.
2018 08; 164(2):477-488. doi:
10.1093/toxsci/kfy101. [PMID: 29688484] - F Belal, F Ibrahim, Z A Sheribah, H Alaa. Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Aug; 1091(?):36-45. doi:
10.1016/j.jchromb.2018.05.030. [PMID: 29843067] - Jong-Suep Baek, Jie Kai Tee, Yi Yun Pang, Ern Yu Tan, Kah Leong Lim, Han Kiat Ho, Say Chye Joachim Loo. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Neuromolecular medicine.
2018 06; 20(2):262-270. doi:
10.1007/s12017-018-8491-0. [PMID: 29696585] - F Belal, F Ibrahim, Z A Sheribah, H Alaa. Micelle-enhanced spectrofluorimetric method for quantification of entacapone in tablets and human plasma.
Luminescence : the journal of biological and chemical luminescence.
2017 Aug; 32(5):713-722. doi:
10.1002/bio.3241. [PMID: 27917581] - Marina Senek, Elisabet I Nielsen, Dag Nyholm. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Movement disorders : official journal of the Movement Disorder Society.
2017 02; 32(2):283-286. doi:
10.1002/mds.26855. [PMID: 27987231] - Jia Li, Zhiwei Lou, Xiaoyang Liu, Yajuan Sun, Jiajun Chen. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
European neurology.
2017; 78(3-4):143-153. doi:
10.1159/000479555. [PMID: 28813703] - Miklós Poór, Zita Zrínyi, Tamás Kőszegi. Structure related effects of flavonoid aglycones on cell cycle progression of HepG2 cells: Metabolic activation of fisetin and quercetin by catechol-O-methyltransferase (COMT).
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2016 Oct; 83(?):998-1005. doi:
10.1016/j.biopha.2016.08.009. [PMID: 27522262] - Mehdi Baghayeri, Maliheh Barazandeh Tehrani, Amirhassan Amiri, Behrooz Maleki, Samaneh Farhadi. A novel way for detection of antiparkinsonism drug entacapone via electrodeposition of silver nanoparticles/functionalized multi-walled carbon nanotubes as an amperometric sensor.
Materials science & engineering. C, Materials for biological applications.
2016 Sep; 66(?):77-83. doi:
10.1016/j.msec.2016.03.077. [PMID: 27207040] - Xia Lv, Xin-Xin Wang, Jie Hou, Zhong-Ze Fang, Jing-Jing Wu, Yun-Feng Cao, Shu-Wen Liu, Guang-Bo Ge, Ling Yang. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
Toxicology and applied pharmacology.
2016 06; 301(?):42-9. doi:
10.1016/j.taap.2016.04.009. [PMID: 27089846] - Yasushi Ishida, Kosuke Ebihara, Masahiro Tabuchi, Sachiko Imamura, Kyoji Sekiguchi, Kazushige Mizoguchi, Yoshio Kase, Go Koganemaru, Hiroshi Abe, Yasushi Ikarashi. Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Biological & pharmaceutical bulletin.
2016; 39(1):104-13. doi:
10.1248/bpb.b15-00691. [PMID: 26725433] - D M Longo, Y Yang, P B Watkins, B A Howell, S Q Siler. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
CPT: pharmacometrics & systems pharmacology.
2016 01; 5(1):31-9. doi:
10.1002/psp4.12053. [PMID: 26844013] - Bilge Kocer, Hayat Guven, Selim Selcuk Comoglu. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?.
BioMed research international.
2016; 2016(?):7563705. doi:
10.1155/2016/7563705. [PMID: 27493964] - M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright, P Soares-da-Silva. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
British journal of pharmacology.
2015 Apr; 172(7):1739-52. doi:
10.1111/bph.13020. [PMID: 25409768] - Rômulo Pereira Ribeiro, João Cleverson Gasparetto, Raquel de Oliveira Vilhena, Thais Martins Guimarães de Francisco, Thais Martins Guimarães de Francisco, Cleverson Antônio Ferreira Martins, Marco André Cardoso, Roberto Pontarolo, Katherine Athayde Teixeira de Carvalho. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Bioanalysis.
2015; 7(2):207-20. doi:
10.4155/bio.14.230. [PMID: 25587837] - Fabrizio Stocchi, Ann Hsu, Sarita Khanna, Aaron Ellenbogen, Andreas Mahler, Grace Liang, Ulrich Dillmann, Robert Rubens, Sherron Kell, Suneel Gupta. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism & related disorders.
2014 Dec; 20(12):1335-40. doi:
10.1016/j.parkreldis.2014.08.004. [PMID: 25306200] - Siegfried Muhlack, Lennard Herrmann, Stephan Salmen, Thomas Müller. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Journal of neural transmission (Vienna, Austria : 1996).
2014 Nov; 121(11):1357-66. doi:
10.1007/s00702-014-1213-3. [PMID: 24770794] - José-Francisco Rocha, Amílcar Falcão, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Lyndon C Wright, Manuel Vaz-da-Silva, Patrício Soares-da-Silva. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
European journal of clinical pharmacology.
2014 Sep; 70(9):1059-71. doi:
10.1007/s00228-014-1701-2. [PMID: 24925090] - Thomas Müller, Siegfried Muhlack. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Journal of neural transmission (Vienna, Austria : 1996).
2014 Jun; 121(6):643-8. doi:
10.1007/s00702-013-1155-1. [PMID: 24390153] - Sarah C Forester, Joshua D Lambert. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Carcinogenesis.
2014 Feb; 35(2):365-72. doi:
10.1093/carcin/bgt347. [PMID: 24148818] - Thomas Müller. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Clinical neuropharmacology.
2013 May; 36(3):84-91. doi:
10.1097/wnf.0b013e31828f3385. [PMID: 23673910] - David J Graham, James R Williams, Ya-Hui Hsueh, Katlyn Calia, Mark Levenson, Simone P Pinheiro, Thomas E Macurdy, David Shih, Chris Worrall, Jeffrey A Kelman. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Movement disorders : official journal of the Movement Disorder Society.
2013 Apr; 28(4):490-7. doi:
10.1002/mds.25351. [PMID: 23443994] - Peng Zhao, Jun-feng Yang, Wei Liu, Yu Wang, Ya-nan Sun, Qi Li, Wei Zhang, Ben-shu Zhang. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhonghua yi xue za zhi.
2013 Feb; 93(7):512-5. doi:
. [PMID: 23660319] - D Nyholm, M Ehrnebo, T Lewander, C G Trolin, T Bäckström, G Panagiotidis, J Spira, C Nyström, S-M Aquilonius. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Acta neurologica Scandinavica.
2013 Feb; 127(2):124-32. doi:
10.1111/j.1600-0404.2012.01700.x. [PMID: 22762460] - Robert N McBurney, Wade M Hines, Linda S VonTungeln, Laura K Schnackenberg, Richard D Beger, Carrie L Moland, Tao Han, James C Fuscoe, Ching-Wei Chang, James J Chen, Zhenqiang Su, Xiao-hui Fan, Weida Tong, Shelagh A Booth, Raji Balasubramanian, Paul L Courchesne, Jennifer M Campbell, Armin Graber, Yu Guo, Peter Juhasz, Tricia Y Li, Moira D Lynch, Nicole M Morel, Thomas N Plasterer, Edward J Takach, Chenhui Zeng, Frederick A Beland. The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.
Toxicologic pathology.
2012 Aug; 40(6):951-64. doi:
10.1177/0192623312444026. [PMID: 22573522] - D Nyholm, A Johansson, H Lennernäs, H Askmark. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
European journal of neurology.
2012 Jun; 19(6):820-6. doi:
10.1111/j.1468-1331.2011.03614.x. [PMID: 22136163] - Kimmo Ingman, Tarja Naukkarinen, Mikko Vahteristo, Irja Korpela, Mikko Kuoppamäki, Juha Ellmén. The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
European journal of clinical pharmacology.
2012 Mar; 68(3):281-9. doi:
10.1007/s00228-011-1121-5. [PMID: 21927836] - Heinz Reichmann, Murat Emre. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Expert review of neurotherapeutics.
2012 Feb; 12(2):119-31. doi:
10.1586/ern.11.203. [PMID: 22288667] - Motomi Arai. Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Neuro endocrinology letters.
2012; 33(7):680-3. doi:
. [PMID: 23391874] - Nenad Manevski, Paolo Svaluto Moreolo, Jari Yli-Kauhaluoma, Moshe Finel. Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Nov; 39(11):2117-29. doi:
10.1124/dmd.111.041418. [PMID: 21856742] - Aiko Ishihara, Takafumi Miyachi, Takeshi Nakamura, Toshiho Ohtsuki, Yasuhiro Kimura, Kenji Kihira, Takemori Yamawaki, Masayasu Matsumoto. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Hiroshima journal of medical sciences.
2011 Sep; 60(3):57-62. doi:
. [PMID: 22053701] - Thomas Müller, Dirk Woitalla, Siegfried Muhlack. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Naunyn-Schmiedeberg's archives of pharmacology.
2011 Jun; 383(6):627-33. doi:
10.1007/s00210-011-0629-7. [PMID: 21533995] - Zhongjian Chen, Meng Chen, Hao Pan, Siyuan Sun, Liping Li, Su Zeng, Huidi Jiang. Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Apr; 39(4):667-74. doi:
10.1124/dmd.110.037333. [PMID: 21209248] - F Bugamelli, C Marcheselli, E Barba, M A Raggi. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Journal of pharmaceutical and biomedical analysis.
2011 Feb; 54(3):562-7. doi:
10.1016/j.jpba.2010.09.042. [PMID: 21035976] - David S Goldstein, Courtney Holmes, LaToya Sewell, Sandra Pechnik, Irwin J Kopin. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Journal of clinical pharmacology.
2011 Jan; 51(1):66-74. doi:
10.1177/0091270010363476. [PMID: 20220040] - Ching-Wei Chang, Frederick A Beland, Wade M Hines, James C Fuscoe, Tao Han, James J Chen. Identification and categorization of liver toxicity markers induced by a related pair of drugs.
International journal of molecular sciences.
2011; 12(7):4609-24. doi:
10.3390/ijms12074609. [PMID: 21845099] - Masahiro Nagai, Madoka Kubo, Noriko Nishikawa, Masahiro Nomoto. Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.
Parkinsonism & related disorders.
2010 Dec; 16(10):697-9. doi:
10.1016/j.parkreldis.2010.08.019. [PMID: 20855228] - Martin Nevrly, Petr Kanovsky, Hana Vranova, Katerina Langova, Petr Hlustik. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
2010 Oct; 31(5):565-9. doi:
10.1007/s10072-010-0262-0. [PMID: 20464572] - Mikael Palner, Patrick McCormick, Jun Parkes, Gitte M Knudsen, Alan A Wilson. Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.
Nuclear medicine and biology.
2010 Oct; 37(7):837-43. doi:
10.1016/j.nucmedbio.2010.04.193. [PMID: 20870159] - Thomas Müller. Entacapone.
Expert opinion on drug metabolism & toxicology.
2010 Aug; 6(8):983-93. doi:
10.1517/17425255.2010.502167. [PMID: 20572781] - Thomas Müller, Siegfried Muhlack. Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Journal of neural transmission (Vienna, Austria : 1996).
2009 Oct; 116(10):1253-6. doi:
10.1007/s00702-009-0275-0. [PMID: 19657587] - Manish Nivsarkar, Aryamitra Banerjee. Establishing the probable mechanism of L-DOPA in Alzheimer's disease management.
Acta poloniae pharmaceutica.
2009 Sep; 66(5):483-6. doi:
. [PMID: 19894644] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - M Nevrly, P Kanovsky, H Vranova, K Langova, P Hlustik. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Parkinsonism & related disorders.
2009 Jul; 15(6):477-8. doi:
10.1016/j.parkreldis.2008.10.005. [PMID: 19028438] - Mikko Kuoppamäki, Kirsi Korpela, Reijo Marttila, Valtteri Kaasinen, Päivi Hartikainen, Jukka Lyytinen, Seppo Kaakkola, Jutta Hänninen, Eliisa Löyttyniemi, Marita Kailajärvi, Päivi Ruokoniemi, Juha Ellmén. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
European journal of clinical pharmacology.
2009 May; 65(5):443-55. doi:
10.1007/s00228-009-0622-y. [PMID: 19229530] - Manish Yadav, Pramod Dixit, Vikas Trivedi, Abhishek Gandhi, Arvind Senger, Swati Guttikar, Puran Singhal, Pranav S Shrivastav. Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Feb; 877(5-6):533-40. doi:
10.1016/j.jchromb.2009.01.004. [PMID: 19167276] - Robert N McBurney, Wade M Hines, Linda S Von Tungeln, Laura K Schnackenberg, Richard D Beger, Carrie L Moland, Tao Han, James C Fuscoe, Ching-Wei Chang, James J Chen, Zhenqiang Su, Xiao-Hui Fan, Weida Tong, Shelagh A Booth, Raji Balasubramanian, Paul L Courchesne, Jennifer M Campbell, Armin Graber, Yu Guo, Peter J Juhasz, Tricin Y Li, Moira D Lynch, Nicole M Morel, Thomas N Plasterer, Edward J Takach, Chenhui Zeng, Frederick A Beland. The liver toxicity biomarker study: phase I design and preliminary results.
Toxicologic pathology.
2009 Jan; 37(1):52-64. doi:
10.1177/0192623308329287. [PMID: 19171931] - Manuela Contin, Paolo Martinelli, Cesa Scaglione, Patrizia Avoni, Fiorenzo Albani, Roberto Riva, Agostino Baruzzi. The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.
Clinical neuropharmacology.
2008 Sep; 31(5):267-71. doi:
10.1097/wnf.0b013e31815c39aa. [PMID: 18836344] - P Damier, F Viallet, M Ziegler, I Bourdeix, K Rerat. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
European journal of neurology.
2008 Jul; 15(7):643-8. doi:
10.1111/j.1468-1331.2008.02165.x. [PMID: 18582341] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Cornelius G Bachmann, Nicolas Guth, Kathrin Helmschmied, Victor W Armstrong, Walter Paulus, Svenja Happe. Homocysteine in restless legs syndrome.
Sleep medicine.
2008 May; 9(4):388-92. doi:
10.1016/j.sleep.2007.06.016. [PMID: 17900981] - Thomas Müller, Kira Kolf, Lema Ander, Dirk Woitalla, Siegfried Muhlack. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Clinical neuropharmacology.
2008 May; 31(3):134-40. doi:
10.1097/wnf.0b013e31811510ed. [PMID: 18520980] - Beatriz Goni-Allo, Brian O Mathúna, Mireia Segura, Elena Puerta, Berta Lasheras, Rafael de la Torre, Norberto Aguirre. The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.
Psychopharmacology.
2008 Apr; 197(2):263-78. doi:
10.1007/s00213-007-1027-1. [PMID: 18074122] - Beatriz Goñi-Allo, Elena Puerta, Brian O Mathúna, Isabel Hervias, Berta Lasheras, Rafael de la Torre, Norberto Aguirre. On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.
Neuropharmacology.
2008 Apr; 54(5):885-900. doi:
10.1016/j.neuropharm.2008.01.007. [PMID: 18329670] - Joaquim J Ferreira, Luis Almeida, Luis Cunha, Marina Ticmeanu, Mário M Rosa, Cristina Januário, Cristina-Elena Mitu, Miguel Coelho, Leonor Correia-Guedes, Ana Morgadinho, Teresa Nunes, Lyndon C Wright, Amílcar Falcão, Cristina Sampaio, Patrício Soares-da-Silva. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Clinical neuropharmacology.
2008 Jan; 31(1):2-18. doi:
10.1097/wnf.0b013e3180645cb0. [PMID: 18303486] - Nils Henninger, Qi Wang, Jürgen G Okun, Stefan Schwab, Martin Krause. Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.
Parkinsonism & related disorders.
2007 Dec; 13(8):524-7. doi:
10.1016/j.parkreldis.2006.11.005. [PMID: 17240187] - Hojjat Sadeghi-Aliabadi, Katie Chan, Hans-Joachim Lehmler, Larry W Robertson, Peter J O'Brien. Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.
Chemico-biological interactions.
2007 May; 167(3):184-92. doi:
10.1016/j.cbi.2007.02.011. [PMID: 17408604] - Thomas Müller, Christoph Erdmann, Siegfried Muhlack, Dirk Bremen, Horst Przuntek, Dirk Woitalla. Entacapone improves complex movement performance in patients with Parkinson's disease.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2007 May; 14(5):424-8. doi:
10.1016/j.jocn.2006.02.008. [PMID: 16790350] - T Müller, L Ander, K Kolf, D Woitalla, S Muhlack. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996).
2007; 114(11):1457-62. doi:
10.1007/s00702-007-0773-x. [PMID: 17564755] - N I Triantafyllou, E Kararizou, E Angelopoulos, S Tsounis, F Boufidou, M E Evangelopoulos, C Nikolaou, D Vassilopoulos. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
European neurology.
2007; 58(2):96-9. doi:
10.1159/000103644. [PMID: 17565222] - T Müller, C Erdmann, S Muhlack, D Bremen, H Przuntek, O Goetze, D Woitalla. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996).
2006 Oct; 113(10):1441-8. doi:
10.1007/s00702-006-0442-5. [PMID: 16604302] - Robert A Hauser. Long-term care of Parkinson's disease. Strategies for managing 'wearing off' symptom re-emergence and dyskinesias.
Geriatrics.
2006 Sep; 61(9):14-20. doi:
NULL. [PMID: 16989543] - R B Postuma, A J Espay, C Zadikoff, O Suchowersky, W R W Martin, A-L Lafontaine, R Ranawaya, R Camicioli, A E Lang. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Neurology.
2006 Jun; 66(12):1941-3. doi:
10.1212/01.wnl.0000219815.83681.f7. [PMID: 16801668] - Theresa A Zesiewicz, Lynn Wecker, Kelly L Sullivan, Lisa R Merlin, Robert A Hauser. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Clinical neuropharmacology.
2006 May; 29(3):106-11. doi:
10.1097/01.wnf.0000220817.94102.95. [PMID: 16772808] - Concepció Marin, Esther Aguilar, José A Obeso. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Movement disorders : official journal of the Movement Disorder Society.
2006 May; 21(5):646-53. doi:
10.1002/mds.20780. [PMID: 16437585] - Thomas Müller, Christoph Erdmann, Siegfried Muhlack, Dirk Bremen, Horst Przuntek, Dirk Woitalla. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Movement disorders : official journal of the Movement Disorder Society.
2006 Mar; 21(3):332-6. doi:
10.1002/mds.20717. [PMID: 16211593] - Thomas Müller, Christoph Erdmann, Dirk Bremen, Wolfgang E Schmidt, Siegfried Muhlack, Dirk Woitalla, Oliver Goetze. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology.
2006 Mar; 29(2):61-7. doi:
10.1097/00002826-200603000-00001. [PMID: 16614536] - Frédéric Libert, François Coudoré, Damien Richard, Franck Durif, Alain Eschalier. Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Journal of mass spectrometry : JMS.
2005 Dec; 40(12):1521-5. doi:
10.1002/jms.939. [PMID: 16285020] - N V S Ramakrishna, K N Vishwottam, S Wishu, M Koteshwara, J Chidambara. High-performance liquid chromatography method for the quantification of entacapone in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Sep; 823(2):189-94. doi:
10.1016/j.jchromb.2005.06.036. [PMID: 16009606] - E Nissinen, H Nissinen, H Larjonmaa, A Väänänen, T Helkamaa, I Reenilä, P Rauhala. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Journal of neural transmission (Vienna, Austria : 1996).
2005 Sep; 112(9):1213-21. doi:
10.1007/s00702-004-0262-4. [PMID: 15614425] - Peter Valkovic, Ján Benetin, Pavol Blazícek, L'udmila Valkovicová, Karin Gmitterová, Peter Kukumberg. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Parkinsonism & related disorders.
2005 Jun; 11(4):253-6. doi:
10.1016/j.parkreldis.2005.01.007. [PMID: 15878587] - Anette Schrag. Entacapone in the treatment of Parkinson's disease.
The Lancet. Neurology.
2005 Jun; 4(6):366-70. doi:
10.1016/s1474-4422(05)70098-3. [PMID: 15907741] - Outi Paija, Kari Laine, Eeva-Riitta Kultalahti, Mika Leinonen, Risto Huupponen, Ariel Gordin, Kari Reinikainen. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Clinical neuropharmacology.
2005 May; 28(3):115-9. doi:
10.1097/01.wnf.0000166393.33781.87. [PMID: 15965309] - A Castro, F Valldeoriola, G Linazasoro, M C Rodriguez-Oroz, F Stochi, C Marin, M Rodriguez, J Vaamonde, P Jenner, L Alvarez, N Pavon, R Macias, M R Luquin, B Hernandez, F Grandas, S Gimenez-Roldan, E Tolosa, J A Obeso. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Neurologia (Barcelona, Spain).
2005 May; 20(4):180-8. doi:
NULL. [PMID: 15891947] - Paolo Lamberti, Stefano Zoccolella, Giovanni Iliceto, Elio Armenise, Angela Fraddosio, Michele de Mari, Paolo Livrea. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Movement disorders : official journal of the Movement Disorder Society.
2005 Jan; 20(1):69-72. doi:
10.1002/mds.20261. [PMID: 15390046] - Katherine L Widnell, Cynthia Comella. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society.
2005; 20 Suppl 11(?):S30-7. doi:
10.1002/mds.20461. [PMID: 15822107] - A Gordin, S Kaakkola, H Teräväinen. Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996).
2004 Oct; 111(10-11):1343-63. doi:
10.1007/s00702-004-0190-3. [PMID: 15340869] - L Brusa, M Pierantozzi, A Bassi, E Fedele, G Lunardi, P Giacomini, P Stanzione. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
2004 Jun; 25(2):53-6. doi:
10.1007/s10072-004-0230-7. [PMID: 15221622] - David J Brooks. Safety and tolerability of COMT inhibitors.
Neurology.
2004 Jan; 62(1 Suppl 1):S39-46. doi:
10.1212/wnl.62.1_suppl_1.s39. [PMID: 14718679] - Teemu Helkamaa, Piet Finckenberg, Marjut Louhelainen, Saara Merasto, Pekka Rauhala, Risto Lapatto, Zhong Jian Cheng, Ilkka Reenilä, Pekka Männistö, Dominik N Müller, Friedrich C Luft, Eero M Mervaala. Entacapone protects from angiotensin II-induced inflammation and renal injury.
Journal of hypertension.
2003 Dec; 21(12):2353-63. doi:
10.1097/00004872-200312000-00025. [PMID: 14654757] - F Blandini, G Nappi, R Fancellu, A Mangiagalli, A Samuele, G Riboldazzi, D Calandrella, C Pacchetti, G Bono, E Martignoni. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996).
2003 Aug; 110(8):911-22. doi:
10.1007/s00702-003-0004-z. [PMID: 12898346] - Tycho Heimbach, Doo-Man Oh, Lilian Y Li, Markus Forsberg, Jouko Savolainen, Jukka Leppänen, Yasushi Matsunaga, Gordon Flynn, David Fleisher. Absorption rate limit considerations for oral phosphate prodrugs.
Pharmaceutical research.
2003 Jun; 20(6):848-56. doi:
10.1023/a:1023827017224. [PMID: 12817887]
